Centre National De La Recherche Scientifique

Université Pierre Et Marie Curie (paris 6)

Université De Rennes 1

Université De Bretagne Occidentale

Centre Hospitalier Universitaire De Brest

Institut National De La Recherche Agronomique

Centre National De La Recherche Scientifique-cnrs

Bertrand Cosson

Christian Berthou

Mirjam Czjzek

Didier Poncet

Hussam Saad

Patrick Cormier

Luc Paillard

Vincent Legagneux

Howard Osborne

Howard Beverley Osborne

Cécile Keryer-Bibens

The invention relates to the A1 peptide of the sequence RRKYGRDFLLRF, as well as to certain variants thereof, for treating cancers, in particular malignant hematopoietic diseases, and more particularly for treating chronic lymphoid leukaemia.

Peptides used for treating cancers and, in particular, chronic lymphoid leukaemia

A peptide protein translation inhibitor has a size greater than 250 amino acids and it includes an amino acid sequence which is at least for 85% identical to an amino acid sequence SEQ ID No 1. It also relates to a fusion polypeptide which specifically inhibits an interesting target polynucleotide translation, in which the polypeptide includes the above defined inhibiting peptide fused with a RNA binding protein.

Peptide protein translation inhibitor and the use thereof for protein translation control

Growing community of inventors

Taulë, France

Bertrand Cosson